Regentis (RGNT) Director Susan Alpert Receives Option Award

What Happened
Susan Alpert, a director of Regentis Biomaterials Ltd. (RGNT), was granted 24,826 derivative securities (an option/award) on July 9, 2026. The Form 4 reports the acquisition at $0.00 per share (derivative award). This is an acquisition-type transaction (award/grant), not a sale.

Key Details

• Transaction date: July 9, 2026; filing date: July 13, 2026 (timely filing).
• Reported amount: 24,826 derivative shares (code A = award/grant). Reported price: $0.00.
• Vesting: Grant approved by the board on June 4, 2026 subject to shareholder approval (obtained July 9, 2026). Vesting occurs quarterly: 1/12 vests on Sept 4, 2026, then an additional 1/12 on the last day of each subsequent three-month period, fully vesting on June 4, 2029, subject to continuous service. (See filing footnotes F1 and F2.)
• Shares owned after transaction: Not specified in the provided filing details.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context
This was a derivative award (options/rights) granted to a director that vests over three years; such awards represent potential future share acquisition if and when vesting and any exercise conditions are met. Because the filing reports an award (not a sale), it indicates acquisition of potential future equity but does not represent an immediate open-market purchase. The filing was submitted on time per SEC Form 4 timing rules.